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Abstract
Type 2 diabetes mellitus (DM) is a major risk factor for developing tuberculosis (TB). TB-DM
comorbidity is expected to pose a serious future health problem due to the alarming rise in
global DM incidence. At present, the causal underlying mechanisms linking DM and TB
remain unclear. DM is associated with elevated levels of oxidized low-density lipoprotein
(oxLDL), a pathologically modified lipoprotein which plays a key role during atherosclerosis
development through the formation of lipid-loaded foamy macrophages, an event which
also occurs during progression of the TB granuloma. We therefore hypothesized that oxLDL
could be a common factor connecting DM to TB. To study this, we measured oxLDL levels
in plasma samples of healthy controls, TB, DM and TB-DM patients, and subsequently
investigated the effect of oxLDL treatment on human macrophage infection with Mycobacte-
rium tuberculosis (Mtb). Plasma oxLDL levels were significantly elevated in DM patients and
associated with high triglyceride levels in TB-DM. Strikingly, incubation with oxLDL strongly
increased macrophage Mtb load compared to native or acetylated LDL (acLDL). Mechanisti-
cally, oxLDL -but not acLDL- treatment induced macrophage lysosomal cholesterol accu-
mulation and increased protein levels of lysosomal and autophagy markers, while reducing
Mtb colocalization with lysosomes. Importantly, combined treatment of acLDL and intracel-
lular cholesterol transport inhibitor (U18666A) mimicked the oxLDL-induced lysosomal phe-
notype and impaired macrophage Mtb control, illustrating that the localization of lipid
accumulation is critical. Collectively, these results demonstrate that oxLDL could be an
important DM-associated TB-risk factor by causing lysosomal dysfunction and impaired
control of Mtb infection in human macrophages.
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Author summary
Tuberculosis (TB) is an infectious disease of the lungs caused by a bacterium, Mycobacte-
rium tuberculosis (Mtb), and is responsible for over a million deaths per year worldwide.
Population studies have demonstrated that type 2 diabetes mellitus (DM) is a risk factor
for TB as it triples the risk of developing the disease. DM is a metabolic disorder which is
generally associated with obesity, and is characterized by resistance to the pancreatic hor-
mone insulin and high blood glucose and lipid levels. As the global incidence of DM is ris-
ing at an alarming rate, especially in regions where TB is common, it is important to
understand precisely how DM increases the risk of developing TB. Both TB and DM are
associated with the development of foamy macrophages, lipid-loaded white blood cells,
which can be the result of a specific lipoprotein particle called oxidized low-density lipo-
protein (oxLDL). Here, we demonstrated that DM patients have high blood levels of
oxLDL, and generating foamy macrophages with oxLDL supported Mtb survival after
infection as a result of faulty intracellular cholesterol accumulation. Our results propose a
proof of concept for oxLDL as a risk factor for TB development, encouraging future stud-
ies on lipid-lowering therapies for TB-DM.
Introduction
Type 2 diabetes mellitus (DM) has been recognized as a major risk factor for tuberculosis (TB)
for decades [1]. Recent epidemiological studies have demonstrated that DM triples the risk of
developing active TB [2], and approximately 15% of global TB cases can be attributed to DM
comorbidity [3]. The precise mechanisms through which DM enhances the risk of active TB
disease progression are unknown, however it has been hypothesized that metabolic changes
associated with DM attenuate the immune response towards Mycobacterium tuberculosis
(Mtb), the causative pathogen of TB. As the global incidence of DM has been rising at an
alarming rate [4], including more recently in TB endemic regions of African and Asia, it is of
great importance to identify the molecular and cellular mechanisms underlying TB-DM
comorbidity.
DM patients often suffer from dyslipidemia and oxidative stress, conditions which can con-
tribute to the formation of oxidized low density lipoprotein (oxLDL) [5]. LDL can be oxidized
by free radicals and reactive products of oxygenases, a process which has been mostly studied
in the context of atherosclerosis during which oxLDL is generated in the subendothelial space
of the arterial wall [6, 7]. High levels of circulating oxLDL were shown to be associated with
DM, insulin resistance and decreased glucose tolerance [8–11]. oxLDL is recognized as a dam-
age-associated molecular pattern (DAMP) by macrophages and is a ligand for various scaven-
ger receptors on the cell surface, including CD36, scavenger receptor A (SR-A) and lectin-type
oxidized LDL receptor 1 (LOX-1) [12]. The uptake of oxLDL by macrophages plays a major
role during the pathophysiology of atherosclerosis as it leads to the generation of pro-inflam-
matory lipid-loaded foam cells in the arterial vessel wall [13, 14]. These macrophages exhibit
increased scavenger receptor expression, cytokine secretion and production of oxidizing
agents, supporting both immune cell infiltration and further generation of oxLDL which can
culminate in atherosclerotic plaque formation [15].
Foamy macrophages also occur during TB progression and are thought to be of great
importance for the development of TB granulomas and persisting Mtb infection, since the bac-
terium relies on host-derived lipids and cholesterol as a source of carbon for its survival [16–
18]. Infection of alveolar macrophages with Mtb initiates the formation of the early TB
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granuloma, which progresses from a core of infected foam cells to an enclosed structure with a
thick fibrous capsule and a lipid-rich caseous center of necrotic macrophages [16]. Various
studies have demonstrated that Mtb and other mycobacteria are able to utilize host-derived
lipids and even reprogram lipid metabolism in infected macrophages to induce foam cell for-
mation, in part through the effects of mycobacterial cell wall lipids [19–24]. Interestingly,
oxLDL was also found to accumulate in granulomas and alveolar macrophages of Mtb infected
guinea pigs and to enhance bacterial replication [25], suggesting that local oxLDL production
could play a role in foam cell formation and Mtb persistence during TB disease.
OxLDL-derived lipids have been demonstrated to be resistant to lysosomal esterases which
are normally responsible for lipid breakdown. This results in lipid accumulation inside lyso-
somes after initial uptake by macrophages [26, 27], as well as to dysfunctions in the trafficking
and efflux of intracellular cholesterol which mimic those observed in the lysosomal storage dis-
order Niemann Pick disease type C (NPC). During NPC disease, mutations in the lysosomal
cholesterol transporters NPC1 or NPC2 result in severe neurological defects due to excessive
intralysosomal storage of cholesterol and sphingolipids [28]. Cholesterol accumulation due to
oxLDL uptake or NPC1-deficiency induces lysosomal dysfunction in macrophages, as it can
interfere with phagolysosomal trafficking, maturation and fusion [29, 30]; inhibit autophagy
[31, 32], an important cellular pathway which is simultaneously involved in lipid and choles-
terol metabolism [33] and Mtb killing [34] in macrophages; increase lysosomal pH [35];
directly damage lysosomal membranes [36, 37]; and trigger various downstream inflammatory
pathways such as formation of the NLRP3 inflammasome [38]. A recent paper demonstrated
that both infection with live M. smegmatis or M. bovis BCG and treatment with mycobacterial
cell wall lipids induced a NPC-like phenotype in macrophages with associated defects in lyso-
somal function [39], indicating that cholesterol accumulation could provide a permissive envi-
ronment for mycobacteria in addition to being a nutritional source.
To investigate whether oxLDL is a molecular component in the interplay between TB and
DM, we measured oxLDL concentrations in plasma samples of DM, TB and TB-DM patients
and analyzed the effect of oxLDL on in vitro Mtb infection in primary human macrophages.
We found that oxLDL is elevated in the plasma of DM patients and supported Mtb intracellu-
lar survival in vitro by inducing lysosomal dysfunction. Collectively, our findings provide a
proof of concept for a contribution of oxLDL as a risk factor for TB during DM.
Results
Plasma oxLDL levels are increased in DM and TB-DM patients with
dyslipidemia
First, we sought to confirm the presence of high levels of circulating oxLDL in DM patients
from a TB endemic setting and to assess the relative impact of TB-DM comorbidity on circu-
lating oxLDL levels. OxLDL concentrations were determined in plasma samples from healthy
endemic controls (HC), TB, DM and TB-DM patients of a South-African cohort, previously
used in a lipidomic biomarker analysis [40], by sandwich ELISA using a monoclonal antibody
against a conformational epitope in oxidized ApoB-100 [41]. Patient characteristics are
described in S1 Table.
Plasma oxLDL levels were significantly higher in DM patients (median: 65.8 [interquartile
range: 39.2–83.2] U/l) compared to both HC (42.3 [35.3–82.2] U/l, p< 0.05) and TB-DM
patients (44.4 [30.3–56.7] U/l, p< 0.05) (Fig 1A), but not significantly different in patients
with TB-DM compared to TB alone (44.3 [29.6–50.0] U/l). However, a clear dichotomy was
distinguishable in the TB-DM patient group: our previous analysis of these samples [40] had
demonstrated that both DM and TB-DM patients displayed characteristics of dyslipidemia, as
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evidenced by high levels of serum triglycerides (TG) (Fig 1B). Furthermore, serum triglycer-
ide levels were positively correlated with oxLDL across all measured samples (r2: 0.4189,
p = 1.155−10) (Fig 1C). To investigate whether oxLDL levels were related to the severity of
dyslipidemia in TB-DM patients, we subdivided the groups according to serum TG-concen-
trations (TG-high and TG-low, Fig 1D). DM and TB-DM patients with TG-high had
increased oxLDL levels compared to those with TG-low (DM: 72.0 [61.7–87.1] vs 46.8
[33.0–76.3] U/l, p = 0.053; TB-DM: 56.4 [52.1–59.4] vs 32.7 [27.2–39.2] U/l, p< 0.05).
Taken together, the results validate that DM patients have increased levels of circulating
oxLDL and that plasma oxLDL concentrations are elevated in DM and TB-DM patients
with concomitant hypertriglyceridemia.
Fig 1. OxLDL levels are increased in DM and associated with triglyceride levels in TB-DM patients. (A) OxLDL concentrations (U/l) were determined in plasma
samples of healthy controls (HC) (n = 20), TB (n = 20), DM (n = 20) and TB-DM patients (n = 19) by ELISA. (B) Serum triglyceride (TG) levels (mmol/l) were
determined by H+-NMR spectroscopy. (C) Linear correlation analysis of log-transformed serum triglyceride and oxLDL levels. (D) Plasma oxLDL concentrations in
HC, TB, DM and TB-DM patients stratified by TG levels (TG-high vs TG-low; n = 10/group except for TB-DM + TG-low: n = 9). Individual patients are depicted as
dots with group medians. Statistical significance was determined by Kruskal-Wallis test with post-hoc Dunn’s test. � = p< 0.05, ��� = p< 0.001.
https://doi.org/10.1371/journal.ppat.1007724.g001
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OxLDL treatment increases Mtb bacterial burden in infected human
macrophages
As oxLDL was clearly elevated in DM patients and has been described to have profound effects
on macrophage function, we hypothesized that oxLDL treatment could compromise the
capacity of macrophages to control Mtb infection. To investigate this, macrophages were
treated with 1, 10 or 25 μg/ml oxLDL or native LDL overnight. Oil Red O staining indicated a
dose-dependent increase in intracellular lipid levels after oxLDL treatment, while native LDL
did not induce foam cells (Figs 2A and S1B). These macrophages were subsequently infected
for 24 h with Mtb H37Rv and intracellular bacterial loads were assessed by bacterial colony
forming unit (CFU) assay. OxLDL treatment significantly increased Mtb load compared to
native LDL at all tested concentrations (1 μg/ml: 136% [113% - 171%] vs 97% [78% - 128%],
p< 0.01; 10 μg/ml: 143% [115% - 167%] vs 110% [102% - 121%], p< 0.01; 25 μg/ml: 230%
[179% - 248%] vs 115% [94.8% - 127%], p< 0.01), and this effect was dose-dependent (25 μg/
ml oxLDL vs 1 μg/ml: p< 0.01; vs 10 μg/ml: p< 0.01) (Fig 2B). The magnitude of the increase
in bacterial load was not correlated with small fluctuations in infectious load (MOI) (S1C Fig).
While these experiments demonstrated that oxLDL treatment supported Mtb persistence in
human macrophages, it was unclear whether this was the result of increased phagocytosis,
reduced intracellular mycobacterial control or enhanced replication. To gain a better under-
standing on the cellular processes affected by oxLDL treatment, we explored the functional
consequences of oxLDL-induced foam cell formation. Firstly, the phagocytic capacity of
oxLDL-treated macrophages was assessed to investigate whether the increased mycobacterial
load might be related to enhanced Mtb uptake. Macrophages treated with either native LDL or
Fig 2. OxLDL-treated macrophages have an increased Mtb burden. Primary human macrophages were treated with PBS control, native LDL or oxLDL (1,
10 or 25 μg/ml) overnight and subsequently infected with Mtb H37Rv at a MOI of 10:1. (A) Oil Red O staining of macrophages treated overnight with PBS,
25 μg/ml LDL or 1, 10 and 25 μg/ml oxLDL. Pictures were taken at a 20x magnification. (B) Macrophages were lysed at 24 h post-infection and bacterial load
was determined by CFU assay. Results were normalized versus PBS control (n = 8). Individual donors are depicted as dots with group medians. Statistical
significance was determined by Wilcoxon signed rank test with post-hoc FDR correction. �� = p< 0.01.
https://doi.org/10.1371/journal.ppat.1007724.g002
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oxLDL were incubated with fluorescent polystyrene beads and bead phagocytosis was quanti-
fied by flow cytometry (Fig 3A). Although a small but significant decrease in bead uptake
was observed in macrophages incubated with 25 μg/ml oxLDL compared to LDL (p< 0.05)
Fig 3. Functional analysis of oxLDL-treated macrophages. Primary human macrophages were treated with PBS control, native LDL or oxLDL (1, 10 or 25 μg/ml)
overnight. (A) Macrophages were incubated with fluorescent phagocytosis beads at a MOI of 10:1 and subsequently analyzed by flow cytometry. Fluorescence of
extracellular beads was quenched with Trypan Blue. (B) Percentage of macrophages with 0, 1 or�2 beads internalized beads (n = 6). Data is represented as means with
standard deviations. (C) Macrophages were infected with Mtb H37Rv at a MOI of 10:1 for 1 h. Supernatants were harvested at 24 h post-infection and concentrations of
TNF-α, IL-6, IL-10 and IL-1β were determined by ELISA (n = 10). Individual donors are depicted as dots with group medians. (D) Macrophages were co-cultured for
four days with the HLA-DR2-restricted CD4+ T cell R2F10 at a ratio of 1:4 and 0.1, 1 or 10 μg/ml of its cognate peptide. T cell proliferation was measured by tritium-
thymidine incorporation during the last 24 h (n = 3). Data is represented as means with standard deviations. Statistical significance was determined by Wilcoxon signed
rank test with post-hoc FDR correction. � = p< 0.05.
https://doi.org/10.1371/journal.ppat.1007724.g003
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(Fig 3B), overall macrophage phagocytic capacity was unaffected by oxLDL treatment, indicat-
ing that the increased mycobacterial burden in oxLDL-derived foam cells was probably not the
result of increased phagocytic uptake. To confirm this, we investigated the intracellular bacte-
rial load of oxLDL-treated macrophages directly after 1 h of infection and found no significant
differences compared to control conditions (S2C Fig).
Next, we explored the cytokine response of oxLDL-derived foam cells to Mtb-infection as
earlier studies had reported potent oxLDL-induced pro-inflammatory cytokine production. In
contrast to these studies, oxLDL-treatment in our experiments significantly decreased the
secretion of TNF-α compared to treatment with LDL (47 [20 – 186] vs 128 [54 – 453] pg/ml,
p< 0.05) or PBS (146 [62 – 466] pg/ml, p< 0.05). Similar results were obtained for IL-6 after
oxLDL treatment versus LDL (11 [0–226] vs 66 [0–553] pg/ml, p< 0.05) or PBS (73 [0–412]
pg/ml, p< 0.05), although some inter-individual variation was observed (Fig 3C). IL-10 levels
were not significantly affected by oxLDL, while IL-1β levels were very low.
Finally, oxLDL-derived macrophages were co-cultured with a HLA-DR2-restricted CD4+ T
cell clone (R2F10) and its cognate peptide (Mlep hsp65 p418–427) and T cell proliferation was
measured to determine macrophage dependent antigen presentation. OxLDL treatment dose-
dependently diminished the antigen presentation capacity of macrophages, especially at subopti-
mal peptide concentrations (Fig 3D). Similar results were obtained using a second, HLA-DR3-
restricted CD4+ T cell clone (Rp15 1–1) (S2A Fig), both after loading with its cognate peptide or
purified protein derivative (PPD). This diminished antigen presentation capacity was indepen-
dent of cell surface expression of HLA-DR and co-stimulatory molecules CD80 and CD86 (S2B
Fig). Taken together, oxLDL treatment impaired several macrophage functions, including anti-
gen presentation and pro-inflammatory cytokine secretion, but not their phagocytic capacity.
OxLDL supports Mtb intracellular survival through lysosomal cholesterol
accumulation
OxLDL-derived free and esterified cholesterol have been demonstrated to be sequestered in
lysosomes in macrophages [26, 27], which potentially leads to lysosomal dysfunction. To
investigate whether lysosomal localization of oxLDL lipids is required for its effect on Mtb
load, oxLDL treatment was compared to acLDL, a non-naturally occurring modified lipopro-
tein which is endocytosed through identical scavenger receptor pathways as oxLDL, but does
not induce lysosomal cholesterol accumulation [26, 42]. In resemblance to oxLDL, acLDL
treatment of macrophages resulted in foam cell formation. However, while lipid staining
intensities were similar (S1B Fig), clear differences in intracellular lipid localization and drop-
let structure were observed between both types of lipoproteins: in general, acLDL-induced
intracellular lipid droplets were darker in color and appeared more granular than those result-
ing from oxLDL treatment (Fig 4A). Most importantly, however, acLDL did not affect macro-
phage Mtb load compared to untreated macrophages while oxLDL treatment significantly
increased mycobacterial load (Fig 4B: oxLDL: 232% [194%– 278%] vs acLDL: 108% [88% -
126%]; p< 0.0001). This effect was not restricted to Mtb, as comparable results were obtained
after macrophage infection with Salmonella enterica serovar Typhimurium (Stm) (Fig 4D:
179% [162% - 183%] vs 124% [88% - 136%]; p< 0.05) and M. bovis BCG (Fig 4C: 178% [133%
- 254%] vs 97% [82% - 123%]; p< 0.05). To examine whether the observed difference between
oxLDL and acLDL could be related to lysosomal function, their effect on lysosomal and autop-
hagy markers during Mtb infection was analyzed by Western blot (Fig 4E). OxLDL treatment
increased protein levels of lysosomal markers compared to PBS and acLDL, as demonstrated
by higher levels of lysosomal membrane glycoproteins (LAMP1 & LAMP2) and proteases
(Cathepsin D & L) (Fig 4F), also including the 48 kDa processing intermediate pro-cathepsin
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D (S3A Fig). Furthermore, oxLDL but not acLDL treatment led to an increased accumulation
of LC3-II in the presence of vacuolar type H+-ATPase inhibitor bafilomycin A1 (10 nM) to
block vesicle breakdown, indicative of increased autophagic flux. In contrast, levels of autopha-
gosome cargo protein p62, a mediator of selective autophagy, were not elevated by oxLDL (Fig
4F). Collectively, these results indicate that oxLDL induces a general defect in macrophage
antimicrobial function which is dependent on intracellular lipid localization.
To further substantiate this hypothesis, macrophages were treated with PBS, oxLDL or
acLDL in the absence or presence of U18666A (3 μg/ml), an inhibitor of intracellular choles-
terol transport [43]. Lysosomal cholesterol sequestration was visualized using confocal
microscopy by staining with fluorescent probes for neutral lipids (LipidTOX), lysosomes
(Lysotracker) and cholesterol (filipin) (Fig 4G). OxLDL treatment induced a marked accumu-
lation of cholesterol inside lysosomal vesicles as indicated by filipin and Lysotracker colocaliza-
tion, which was not observed in macrophages treated with PBS or acLDL. Strikingly, when
combined with U18666A, acLDL-treated macrophages showed identical lysosomal cholesterol
sequestration as oxLDL. The absence of an effect of acLDL treatment alone on Mtb load sug-
gested that the localization of cholesterol inside lysosomes might be a causative factor in the
increased Mtb growth phenotype of oxLDL-treated macrophages. To test this, we investigated
whether combined treatment of acLDL with U18666A could mimic the effect of oxLDL on
macrophage Mtb control. Indeed, while U18666A alone or in combination with oxLDL did
not significantly alter macrophage phenotype (Fig 4G) and Mtb load, it increased mycobacte-
rial burden when applied in conjunction with acLDL compared to DMSO control (Fig 4H:
169% ± 62% vs 107% ± 32%; p< 0.05). Similar to oxLDL, U18666A treatment alone and in
combination with acLDL increased protein levels of lysosome and autophagy markers in Mtb-
infected macrophages, most notably Cathepsin L and when combined with bafilomycin A1
(10 nM), p62 and LC3-II (S3B Fig). Macrophage viability was unaffected by oxLDL and/or
U18666A treatment in combination with Mtb infection as determined by combined Hoechst/
propidium iodide (PI) staining (S3C and S3D Fig). Collectively, these results indicate that not
simply the presence, but the specific accumulation of cholesterol inside lysosomes is crucial for
the oxLDL- and U18666A-induced increase in Mtb survival in human macrophages.
While the above model proposes that oxLDL can interfere with macrophage mycobacterial
control, we could not yet exclude whether oxLDL-induced foam cell formation also supported
Mtb replication, possibly by providing increased nutrients. To gain a better understanding of
overall kinetics of oxLDL-induced increased Mtb load and its associated cytokine response,
infected macrophages treated with PBS control, oxLDL or acLDL were infected with Mtb and
the intracellular bacterial load and concentrations of 29 cytokines and chemokines in superna-
tants were determined at 0 (uptake control), 4, 24, 48, 72 and 144 h post-infection. OxLDL
treatment showed increased Mtb survival compared to PBS as early as 4 h post-infection, and
versus both PBS and acLDL at all later time points (24–144 h) (S4A Fig). For all treatment
Fig 4. Lysosomal cholesterol accumulation attenuates macrophage Mtb control. Primary human macrophages were treated with PBS control, acLDL or oxLDL (25 μg/
ml) overnight. (A) Oil Red O staining of macrophages treated overnight with 25 μg/ml acLDL or oxLDL. Pictures were taken at a 20x magnification. Macrophages were
infected with Mtb H37Rv (B) (n = 32), M. bovis BCG (C) (n = 6) or Salmonella enterica serovar Typhimurium (D) (n = 6) at a MOI of 10:1. Cells were lysed at 24 h post-
infection and bacterial load was determined by CFU assay. Results were normalized versus PBS control. (E) Western blot analysis of lysosomal and autophagy markers in
macrophages treated with bafilomycin A1 (10 nM) or DMSO control during 24 h of H37Rv Mtb infection. Data shown is from one representative donor (n = 4). (F)
Quantification of LAMP1, LAMP2, Cathepsin D, Cathepsin L (+ DMSO), p62 and LC3-II (+ bafilomycin A1) protein levels. Protein levels were first normalized to actin
and subsequently versus PBS control (n = 4). (G) Macrophages were co-treated with U18666A (3 μg/ml) or DMSO control for 24 h. Cells were subsequently stained for
neutral lipids (LipidTOX, green), lysosomes (Lysotracker, red) and cholesterol (filipin, blue) and analyzed by confocal microscopy. Pictures were taken at a 63x
magnification. Scale bars represent 5 μM. (H) Macrophages were co-treated with U18666A (3 μg/ml) or DMSO control for 24 h pre- and post-infection with Mtb H37Rv
at a MOI of 10:1. Cells were lysed at 24 h post-infection and bacterial load was determined by CFU assay. Results were normalized versus PBS control (+ DMSO).
Individual donors are depicted as dots with group medians. Statistical significance was determined by Wilcoxon signed rank test. � = p< 0.05, ���� = p< 0.0001.
https://doi.org/10.1371/journal.ppat.1007724.g004
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conditions the intracellular Mtb load decreased with time, ranging from 1.3 to 12.4% of origi-
nal bacterial uptake after 144 h of infection, which is supportive of a model in which the effect
of oxLDL is the result of inhibited bacterial killing and not of increased bacterial outgrowth.
The multiplex results were congruent with the ELISA data from Fig 3C, as oxLDL-treated
macrophages produced significantly lower levels of TNF-α and IL-6 after 24 h of Mtb infection
compared to PBS control (S4B Fig). Many cyto- and chemokine concentrations were lower in
oxLDL-treated macrophages between 4–48 h of Mtb infection, while supernatants from
acLDL-treated macrophages often showed intermediate levels compared to PBS and oxLDL
(IL-10, IL-6, TNF-α, IL-8, CCL3, CCL4, G-CSF, GM-CSF). We did not find significant differ-
ences at 72 and 144 h post-infection after FDR correction. IL-1RA was the only cytokine
which showed increased production as a result of oxLDL, although the magnitude of this
response varied between donors. Concentrations of CXCL10, IFNα2, CCL2 and VEGF
increased as a result of Mtb infection, however no differences were observed between treat-
ment conditions for these factors. Levels of Epidermal Growth Factor (EGF), Eotaxin, IFNγ,
IL-12p40, IL-12p70, IL-1β, IL-13, IL-15, IL-17A, IL-1α, IL-2, IL-3, IL-4, IL-5, IL-7 and TNF-β
were measured but not shown as their concentrations were either very low in all samples
(<100 pg/ml) or not detectable. Taken together, these experiments provide further evidence
for an overall diminished cytokine response as a result of oxLDL treatment during Mtb
infection.
OxLDL-inhibited mycobacterial killing is not rescued by small-molecules
targeting known downstream signaling pathways
To identify the relevant molecular processes which are deregulated by lysosomal cholesterol
accumulation, oxLDL-treated macrophages infected with Mtb were treated with compounds
targeting various cell signaling pathways which are known to be affected by oxLDL in an
attempt to rescue their antimicrobial capacity. Firstly, infected foamy macrophages were
treated with rapamycin, an inhibitor of mammalian target of rapamycin complex 1
(mTORC1). mTOR is a master regulator of various cellular pathways including autophagy,
and rapamycin-induced autophagy was reported to ameliorate foam cell formation [44, 45].
Rapamycin (2 μM) slightly but significantly reduced Mtb load compared to DMSO in PBS-
treated macrophages (80 ± 15% of PBS/DMSO, p< 0.05), but did not affect bacterial burden
in either oxLDL or acLDL-induced foamy macrophages (Fig 5A). Secondly, lysosomal stor-
age disorders such as NPC disease are associated with defects in lysosomal Ca2+ homeostasis
[46], and activation of the lysosomal ion channel transient receptor potential channel 1
(TRPML1) by small-molecule activator ML-SA1 was shown to rescue lysosomal trafficking
in NPC-/--macrophages [30]. However, ML-SA1 treatment (10 μM) did not affect Mtb infec-
tion in any of our conditions (Fig 5B). Finally, oxLDL can induce endoplasmic reticulum
(ER) stress in macrophages [47], a state of disturbed ER homeostasis due to accumulation of
unfolded proteins and/or disrupted Ca2+ handling which plays a role in the apoptotic response
in atherosclerotic plaques and the TB granuloma [48, 49]. Treatment of Mtb-infected macro-
phages with three established reducers of the ER stress response, namely chemical chaperone
4-phenylbutyrate (4-PBA; 3 mM) and downstream kinase inhibitors 4μ8c (10 μM) and
GSK2656157 (10 μM) (respectively targeting inositol-requiring enzyme 1-α (IRE1-α) and pro-
tein kinase RNA-like endoplasmic reticulum kinase (PERK)), did not alleviate the oxLDL-
induced increase in mycobacterial survival (Fig 5C). In conclusion, chemical modulation of
mTOR signaling, lysosomal Ca2+ homeostasis or ER stress did not reverse the oxLDL-induced
increased mycobacterial load in human macrophages.
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OxLDL inhibits Mtb localization to functional lysosomes in infected
macrophages
The above experiments demonstrated that the endolysosomal system is pivotal for oxLDL-
induced increased mycobacterial survival. As earlier studies have reported that cholesterol
accumulation impaired proper lysosomal trafficking [29, 30], we hypothesized that Mtb traf-
ficking to functional lysosomes was inhibited by oxLDL treatment. To investigate this, oxLDL-
treated macrophages infected with fluorescent DsRed-expressing H37Rv were stained for
functional lysosomes with Lysotracker (Fig 6A), and lysosomal colocalization was determined
for each intracellular mycobacterium individually (Fig 6B). OxLDL significantly decreased the
average colocalization between Mtb and Lysotracker (39 ± 9%) compared to acLDL (51 ± 12%,
p< 0.05) or PBS treatment (60 ± 6%, p< 0.05) (Fig 6C), indicating that oxLDL inhibits phago-
lysosomal fusion in Mtb-infected macrophages.
In an attempt to identify the specific lysosomal pathways affected by oxLDL treatment, we
investigated colocalization of Mtb with galectin-3 and NDP52. Galectins are carbohydrate-
binding proteins which play a role in targeting damaged endomembrane structures for autop-
hagy [50], including phagolysosomes damaged by Stm or Mtb [51–53], and galectin-3 colocali-
zation with lysosomes is an established measure of lysosomal damage [54]. NDP52 is an
autophagy adaptor which has previously been implicated in the autophagic clearance of both
Stm and Mtb [51, 55, 56]. Although colocalization events with Mtb were observed for both
galectin-3 and NDP52, this occurred for a minority of intracellular bacteria (range 2–8% of
Fig 5. oxLDL-induced Mtb survival was not reversed by targeting known downstream pathways. Primary human macrophages were treated with PBS control,
acLDL or oxLDL (25 μg/ml) overnight and subsequently infected with Mtb H37Rv at a MOI of 10:1 and treated with compounds or DMSO control overnight. Cells
were lysed at 24 h post-infection and bacterial load was determined by CFU assay. The following treatments were applied: (A) rapamycin (2 μM, n = 6) to induce
mTORC1-regulated autophagy, (B) ML-SA1 (10 μM, n = 6) to stimulate lysosomal Ca2+ release and (C) 4-PBA (3 mM, n = 7), 4μ8c (10 μM, n = 3) and GSK2656157
(10 μM, n = 3) to inhibit the ER stress response. Individual donors are depicted as dots with group medians. Results were normalized versus PBS control (+ DMSO).
Statistical significance was determined by Wilcoxon signed rank test. � = p< 0.05.
https://doi.org/10.1371/journal.ppat.1007724.g005
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Fig 6. oxLDL impairs Mtb localization to lysosomes in macrophages. Primary human macrophages were treated overnight with PBS control, acLDL or oxLDL (25 μg/
ml) and subsequently infected with DsRed-Mtb H37Rv (red) at a MOI of 10:1. Cells were stained (green) for lysosomes (Lysotracker) (A), galectin-3 (D) or NDP52 (F)
at 4 h post-infection and analyzed by confocal microscopy. Pictures were taken at a 63x magnification. Scale bars represent 5 μM. Percentage overlap of intracellular
mycobacteria with staining was determined for 3 wells � 3 = 9 pictures per condition. (B) Results of a representative donor of Mtb overlap with Lysotracker. Individual
mycobacteria are represented by dots with group medians. Average colocalization of Mtb with Lysotracker (C), galectin-3 (E) and NDP52 (G) are displayed for
macrophages from six independent donors. Individual donors are depicted as dots with group medians. Statistical significance was determined by Wilcoxon signed rank
test with post-hoc FDR correction. � = p< 0.05.
https://doi.org/10.1371/journal.ppat.1007724.g006
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bacteria) and no significant differences were found between oxLDL and control conditions
(Fig 6D–6G).
Discussion
The looming epidemic of concurrent TB-DM poses a serious global health problem. Identifica-
tion of the causal molecular and cellular mechanisms underlying the increased risk of TB in
DM patients is paramount for adequate treatment. Previously, we have demonstrated that
TB-DM patients have a blood lipid profile with pro-atherogenic properties [40], which could
have implications for TB-DM pathogenesis. We now identify oxLDL as a potential risk factor
for TB. OxLDL levels were found to be increased in plasma samples of DM patients from a TB
endemic region, who represent the specific population at increased risk for disease. Although
both triglyceride and oxLDL levels were lower in the TB-DM group compared to DM, this
might well be related to the duration and severity of DM disease as the majority of TB-DM
patients were recently diagnosed diabetics compared to the DM alone group (S1 Table). Fur-
thermore, TB was associated with wasting syndrome and therefore with low levels of many cir-
culating metabolites in this patient population, including LDL [40]. As these patients were not
merely at increased risk of TB at the moment of blood collection but had already developed
active disease, it is not unlikely that oxLDL levels are decreased since onset of TB. Nonetheless,
a clear dichotomy in oxLDL concentrations was visible based on triglyceride-status in TB-DM
patients, implying that diabetes-associated dyslipidemia was a factor associated with increased
oxLDL levels in this population.
Importantly, oxLDL-, but not acLDL-, induced foamy macrophage formation supported
intracellular Mtb survival through lysosomal cholesterol accumulation and subsequent dys-
function. This effect was not limited to Mtb as similarly enhanced bacterial loads were
observed for Stm and M. bovis BCG, which reside in different intracellular compartments
compared to Mtb [57]. Pharmacological manipulation of intracellular cholesterol transport
with U18666A confirmed that subcellular localization of cholesterol to lysosomes was essential
to lysosomal dysfunction. Since foamy macrophages play an important role during progres-
sion of the TB granuloma [16, 18], our results suggest that increased levels of oxLDL could
contribute to the enhanced TB susceptibility in DM patients.
Our findings are in line with earlier studies that reported increased levels of oxLDL in DM
patients [8–11]. Both hyperglycemia and dyslipidemia contribute to the generation of free rad-
icals and oxidative stress during chronic DM [58, 59], which can lead to the pathological modi-
fication of proteins and lipids involved in foam cell formation and atherosclerosis, such as
oxLDL. Additionally, DM and hyperglycemia are associated with increased expression of
oxLDL scavenger receptors CD36 [60–62], SR-A [62, 63] and LOX-1 [62, 64], and macro-
phages from type 2 diabetics showed higher uptake of oxLDL [65]. Similar to DM, TB has
been demonstrated to result in increased oxidative stress and a systemic decrease in antioxi-
dant capacity, e.g. reduced levels of glutathione [66–69]. Mtb infection increased CD36 expres-
sion in vitro [19] and CD36-mediated uptake of surfactant lipids has been reported to support
Mtb growth [20]. In contrast, a recent paper did not find a role for CD36-mediated macro-
phage lipid droplet formation in Mtb control [70], which could indicate that not simply the
presence of lipid droplets but rather the specific composition and/or localization of the intra-
cellular lipids is most important for their effect on Mtb intracellular survival, similar to what
we observed here when comparing acLDL and oxLDL.
At the functional level, oxLDL treatment displayed potential to inhibit macrophage antigen
presentation to CD4+ T cells, which could in principal lead to impaired activation of adaptive
immune responses. While their phagocytic capacity was largely unaffected, oxLDL-treatment
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macrophages showed an overall decreased cytokine production in response to Mtb. These
results were somewhat surprising, as oxLDL has been associated with increased inflammation
during atherosclerosis [71] and non-alcoholic steatohepatitis (NASH) [72–74], including acti-
vation of the NLRP3 inflammasome and subsequent secretion of IL-1β by macrophages [38,
75]. However, in these studies oxLDL treatment was often accompanied by secondary factors
which may be required for the observed pro-inflammatory responses, such as macrophage
apoptosis, circulating anti-oxLDL immune complexes or the formation of intralysosomal cho-
lesterol crystals. In agreement with our own observations, several studies reported diminished
inflammatory responses of oxLDL-treated macrophages after stimulation with TLR ligands
[76–78]. These divergent results could be related to study-specific differences in experimental
setup, including variations in species, cell types, stimulations and degree of LDL oxidation.
Additionally, oxLDL was reported to induce a long-lasting pro-inflammatory phenotype in
monocytes through epigenetic changes, which possibly did not occur in our experiments due
to their relatively short timeframe or lack of restimulation [79, 80].
Hypercholesterolemia has been implicated in increasing the risk of developing TB [81–83],
and cholesterol catabolism is needed for mycobacterial persistence and growth [84, 85]. For
this reason, most studies on foamy macrophage induction by mycobacteria have focused on
the relatively long-term nutritional benefits of intracellular lipid accumulation [20, 86]. The
results presented in this manuscript demonstrate that pathologically modified lipids also
directly interfere with macrophage antimicrobial capacities, providing a novel perspective on
the importance of foam cell formation during TB. These findings are corroborated by a study
which demonstrated that M. smegmatis and M. bovis BCG blocked phagolysosomal fusion by
inducing an NPC-like phenotype in infected macrophages [39]. Additionally, macrophage
cholesterol depletion restored halted phagosome maturation during M. avium infection [87].
Drugs which target host cholesterol metabolism can therefore have potential for TB host
directed treatment, and e.g. statins have shown promise as adjunctive anti-mycobacterial ther-
apy both in vitro and in vivo [88–92]. Furthermore, our results suggest that oxLDL treatment
supports mycobacterial survival through interference with phagolysosomal trafficking and/or
fusion. Lysosomal lipid accumulation has been reported to influence these processes in several
ways. Late endosomal transport is mediated by the lysosomal protein ORP1L, which modu-
lates the interaction between Rab GTPases and their effectors, motor protein complexes and
the ER through conformational changes induced by fluctuations in intraluminal cholesterol
levels [93, 94]. Furthermore, abnormal sphingolipid storage due to NPC1-deficiency or
U18666A treatment was shown to disrupt lysosomal Ca2+ homeostasis, blocking vesicle trans-
port and fusion [30, 46]. Finally, several studies have reported that lysosomal storage disorders
interfere with the autophagic system [31, 32], which might be reflected by the increased LC3-II
levels detected in oxLDL- and U18666A-treated macrophages during Mtb infection. Although
pharmacological modulation of these pathways did not ameliorate the oxLDL-induced effect
on Mtb control, their involvement should not yet be excluded as the phenotype induced by
oxLDL was practically irreversible in our experimental setup.
Our study might have had a number of limitations. Firstly, the oxLDL used throughout this
manuscript was generated by copper-induced oxidation of native LDL, which is sometimes
referred to as extensively oxidized LDL in literature due to its high oxidation grade [6]. It is
generally believed that naturally occurring oxLDL is composed of less extensively oxidized var-
iants as abundantly oxidized LDL would be rapidly cleared from the circulation. Therefore, it
is possible that the phenotypes observed in our experiments are more extreme than would
have occurred using naturally oxidized LDL. However, the precise composition of physiologi-
cal oxLDL is still uncertain as accurate characterization of isolated oxLDL is technically chal-
lenging. As LDL oxidation mostly occurs in the subendothelial space during atherosclerosis,
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locally generated oxidized species might be of greater importance for disease than circulating
oxLDL. Regardless, it would be of interest to investigate the effects of minimally modified LDL
(mmLDL), a variant which is believed to be more similar to naturally occurring oxLDL [6], on
macrophage Mtb infection. Secondly, oxLDL was applied at a concentration of 25 μg/ml for
the majority of the experiments, which is at the high end of what has been physiologically
observed [95–97]. However, oxLDL treatment times were relatively short compared to what
can be expected in vivo, and low levels of oxLDL (1 μg/ml) were already sufficient to increase
mycobacterial load during this period. Thirdly, oxLDL is a complex particle consisting of hun-
dreds of phospholipids, triglycerides and cholesteryl esters, which vary in terms of composi-
tion and susceptibility to oxidation and therefore have different intracellular effects [12]. It
would be of great interest to study whether specific oxidized lipids or proteins are required for
the observed oxLDL phenotype. Finally, although not within the scope of this study and tech-
nically challenging, it would be important to validate these findings in a disease model for
translation to in vivo settings, e.g. using monocytes isolated from DM patients.
In conclusion, oxLDL treatment of human macrophages supports Mtb intracellular survival
as a result of lysosomal dysfunction, providing a proof of concept for a contribution of
increased levels of oxLDL as a potential risk factor for TB development during DM. While we
previously demonstrated that hyperglycemia alone did not directly influence outcome of mac-
rophage Mtb infection [98], we postulate that elevated lipid levels, which are associated with
DM, can be in involved in TB-DM pathogenesis [40]. These findings pave the way for further
research, including the use of LDL-lowering drugs such as statins or antioxidant drugs as part
of the DM-treatment regimen for the reduction of the risk of TB.
Materials and methods
Ethics statement/Patient population and plasma oxLDL measurements
The patient population was previously used in an extensive lipid profiling analysis using H+-
NMR spectroscopy as part of an EU-funded collaborative project, TANDEM [99], of which
details regarding patient inclusion were reported earlier [40]. From this population plasma
samples of 20 healthy endemic controls, 20 TB patients, 20 DM patients and 20 TB-DM
patients were selected at random for oxLDL determination. Plasma oxLDL levels were mea-
sured by sandwich ELISA according to manufacturer’s instructions (Mercodia AB, Uppsala,
Sweden). One TB-DM patient was excluded post-hoc due to the presence of clinical evidence
suggestive of type 1 diabetes, while all other DM patients suffered from type 2 diabetes. This
study was approved by the Health Research Ethics Committee of the University of Stellen-
bosch, and conducted according to the Helsinki Declaration and International Conference of
Harmonization guidelines. Written informed consent was obtained from all participants.
Reagents and antibodies
Primary antibodies against LAMP1, LAMP2, Cathepsin D, Cathepsin L, p62, galectin-3 and
secondary goat anti-mouse IgG (Alexa Fluor 647) were purchased from Abcam (Cambridge,
UK). LC3A/B was from Cell Signaling (Bioke, Leiden, The Netherlands), actin-HRP from
Santa Cruz Biotechnology (Santa Cruz, CA, USA), CD86-Alexa700 and HLA-DR-PeCy5 from
BD Biosciences (Erembodegem, Belgium) and CD80-BV650, CD14-FITC and CD163-A-
lexa647 were bought from Biolegend (ITK diagnostics, Uithoorn, The Netherlands). NDP52
(CALCOCO2), secondary goat anti-rabbit IgG (Alexa Fluor 647) and HRP-conjugated anti-
bodies reactive with mouse and rabbit were purchased from Thermo Fisher Scientific (Merel-
beke, Belgium).
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LDL isolation
LDL was isolated from the serum of healthy volunteers by density gradient ultracentrifugation
[100]. Blood was collected in clot activator tubes and clotted for 90 minutes at room tempera-
ture. Serum was obtained after 10 minutes of centrifugation at 1,500 g. EDTA was added to a
final concentration of 1 mM, after which serum density was adjusted to 1.21 g/l by addition of
solid potassium bromide and gentle stirring. The resulting serum solution was distributed
over 13.7 ml UltraClear ultracentrifuge tubes (Beckman Coulter, Woerden, The Netherlands)
and a density gradient was prepared by overlaying it with potassium bromide solutions of
decreasing concentrations (1.063 g/l, 1.019 g/l, 1.0063 g/l) in PBS supplemented with 0.3 mM
EDTA (pH 7.4) using a wide bore pipette tip. The serum was then centrifuged at 40,000 RPM
for 20 h at 4˚C in a SW41 Ti swinging bucket rotor (Optima LE-80K, Beckman Coulter). After
centrifugation the tubes were carefully removed from the rotor and the LDL fraction was aspi-
rated using a glass Pasteur pipette. The LDL was dialyzed against PBS at 4˚C for 16 h during
which the buffer was refreshed three times. The protein concentration of LDL was determined
using a BCA kit according to the manufacturer’s instructions (Pierce, Thermo Fisher
Scientific).
Generation of oxLDL and acetylated LDL (acLDL)
OxLDL was generated by copper oxidation of native LDL. Copper sulfate was added to 200 μg/
ml LDL in PBS at a final concentration of 5 μM and incubated for 20 h at 37˚C in the dark.
The reaction was stopped by addition of 0.2 mM EDTA and oxLDL was then dialyzed against
PBS containing 1 mM EDTA at 4˚C for 24 h during which the buffer was refreshed three
times. To produce acLDL, LDL was acetylated according to the protocol by Fraenkel-Conrat
et al. [101]. An equal volume of saturated sodium acetate was added to 1 mg/ml of LDL and
stirred at 4˚C until cold. During the following hour acetic anhydride was added in 2 μl aliquots
until 1.5x the mass of LDL was added in total. The mixture was stirred for another 30 minutes
after the last aliquot was added. The acLDL was then dialyzed against PBS containing 1 mM
EDTA at 4˚C for 24 h during which the buffer was refreshed three times. Finally, the modified
lipoproteins were concentrated to 1 mg/ml using 100 kDa Amicon Ultracel centrifugal filter
units (Merck Millipore, Amsterdam, The Netherlands).
Macrophage differentiation and foam cell generation
CD14+ monocytes were isolated from buffy coats of healthy blood bank donors by positive
selection using an autoMACS Pro Separator (Miltenyi Biotec BV, Leiden, The Netherlands).
Donors were not part of an already-existing collection. Monocytes were differentiated into
macrophages by addition of 50 ng/ml macrophage-colony stimulating factor (M-CSF) (Milte-
nyi Biotec) during culture for 6 days at 37˚C/5% CO2 [102]. Cells were cultured in RPMI-1640
medium with L-glutamine, without glucose and sodium bicarbonate (Sigma-Aldrich Chemie
BV, Zwijndrecht, the Netherlands), supplemented with 5 mM D-glucose, 2 g/l sodium bicar-
bonate, 10% fetal bovine serum, 100 units/ml penicillin and 100 μg/ml streptomycin. After dif-
ferentiation macrophages were harvested by trypsinization and seeded in multi-well plates. As
a quality control, macrophages were stained for surface expression of CD14 and CD163 and
acquired on a BD LSRFortessa flow cytometer (BD Biosciences) (S1A Fig). To generate foam
cells, macrophages were treated with various concentrations of oxLDL overnight. PBS, native
LDL and/or acLDL were used as controls. Foam cell formation was confirmed by Oil Red O
staining. Macrophages were fixed for 30 minutes in 4% paraformaldehyde and subsequently
stained with a filtered work solution of Oil Red O (Sigma-Aldrich) in isopropanol (0.3% Oil
Red O in 60% isopropanol) for 20 minutes. Afterwards, the red stain was dissolved in 4% NP-
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40 in isopropanol and quantified by measuring the optical density (OD) at 520 nm using a
iMark Microplate Absorbance Reader (Bio-Rad, Veenendaal, The Netherlands).
Mtb H37Rv infection and cytokine measurements
Mtb H37Rv cultures were grown to mid-log phase in Middlebrook 7H9 liquid medium (Difco,
BD Biosciences) supplemented with albumin/dextrose/catalase (ADC) (BBL, BD Biosciences).
Bacterial concentrations were determined by measuring culture optical density at 600 nm.
Macrophages were infected with H37Rv at a multiplicity of infection (MOI) of 10:1 for 1 h at
37˚C, after which the cells were washed twice with medium containing 30 μg/ml gentamicin
and cultured overnight in fresh medium containing 5 μg/ml gentamicin. Infected cells were
lysed either directly after infection or at 4, 24, 48, 72 or 144 h post-infection using 0.05% Triton
X-100 and a dilution series of the lysates was plated on 7H10 square agar plates (Difco, BD Bio-
sciences) supplemented with oleate/albumin/dextrose/catalase (OADC) (BBL, BD Biosci-
ences). Colony-forming units (CFU) were determined after 2–3 weeks of incubation at 37˚C.
From some experiments supernatants were harvested and filtered for determination of IL-1β,
IL-6, TNF-α (Invitrogen, Thermo Fisher Scientific) and IL-10 (Sanquin, Amsterdam, The
Netherlands) by ELISA or for testing using a Human Cytokine/Chemokine Immunology Mul-
tiplex Assay (Merck Millipore, Amsterdam, the Netherlands) according to their manufactur-
ers’ instructions.
Phagocytosis assay
To quantify phagocytic capacity, fluorescent polystyrene particles (Fluoresbrite YG carboxylate
microspheres) (Polysciences, Hirschberg an der Bergstrasse, Germany) were used as described
by Leclerc et al [103]. Macrophages were incubated with fluorescent beads in a ratio of 10
beads to 1 cell for 90 min at 37˚C. Cells were subsequently harvested by gentle scraping and
resuspended in a 1:1 mixture of culture medium and Trypan Blue, and internalization of the
beads was quantified by acquisition on a BD Accuri C6 flow cytometer (BD Biosciences).
Non-internalized bead fluorescence was quenched by Trypan Blue and detected in the FL-3
channel (red), whereas internalized beads were detected in the FL-1 channel (green). Analysis
was performed using Flowjo software (version 10.1, Tree Star Inc, Ashland, OR).
Antigen presentation assay
HLA-DR2/HLA-DR3-postive macrophages were harvested, seeded in 96-well plates at 2,500
cells/wells and treated with PBS, 25 μg/ml oxLDL or native LDL. The following day the cells
were washed once in assay medium (IMDM with 10% human serum) and HLA class II
restricted CD4+ T cell clones were added at a ratio of 4:1 together with a dilution series of their
specific cognate peptide (R2F10 clone: HLA-DR2 restricted, reactive with Mycobacterium
leprae (Mlep) hsp65; Rp15 1–1: HLA-DR3 restricted, reactive with Mtb and Mlep hsp65) or
1.25 μg/ml purified protein derivative (PPD) (Staten Serum Institute, Copenhagen, Denm-
mark) [104, 105]. Medium was used as negative control. Macrophages and T cells were co-cul-
tured for 3 days at 37˚C/5% CO2, and tritium-thymidine was added for the last 16 h of culture
after which the cells were harvested and tritium-thymidine incorporation was measured using
a Microbetaplate counter (Wallac, Turku, Finland). Furthermore, macrophages were stained
for surface expression of CD86, CD80 and HLA-DR and analyzed on a BD LSRFortessa flow
cytometer (BD Biosciences).
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Western blotting
For analysis of lysosomal and autophagy-related proteins, (Mtb-infected) macrophages were
lysed for 5 minutes using a buffer containing 3% SDS, 4 mm glycerol, 100 mM Tris-HCl (pH
6.8) containing protease inhibitors (Roche, Woerden, The Netherlands) and the resulting
lysates were boiled for 10 min at 95˚C. Protein concentrations were determined by bicinchoni-
nic acid assay (Pierce, Thermo Fisher Scientific) and equal amounts were mixed with 4x
Laemmli buffer before loading on a 4–20% Mini-PROTEAN TGX precast protein gel (Bio-
Rad). After separation, proteins were transferred onto a polyvinylidene fluoride membrane
and blocked for 1 h in Tris-buffered saline/2.5% Tween-20 containing 5% non-fat dry milk
and subsequently probed with primary antibodies overnight at 4˚C. Membranes were incu-
bated with horseradish peroxidase-conjugated secondary antibodies (reactive against mouse
or rabbit) for 2 h at room temperature before visualization by Amersham Enhanced Chemilu-
minescence Western Blotting Detection kit (GE Healthcare, Hoevelaken, The Netherlands).
Blots were quantified using Image J (NIH, Bethesda, MD, USA) and proteins were normalized
versus actin.
Confocal microscopy
For confocal microscopy, macrophages were seeded in black poly-d-lysine coated glass
96-well plates (MatTek Corporation, Ashland, MA, USA). To stain lysosomes, macrophages
were incubated with 75 nM Lysotracker Red or Deep Red (Thermo Fisher Scientific) at
37˚C/5%CO2 for 1 h before fixation. Cells were fixed for 1 h in 1% EM-grade formaldehyde,
followed by quenching with PBS/1.5 mg/ml glycine for 10 min and blocking in 5% human
serum for 45 min, all at room temperature. For immunostaining, cells were permeabilized
for 10 minutes with 0.1% Triton X-100 before blocking and subsequently stained with pri-
mary and secondary antibodies for 30 minutes each in the dark at room temperature.
Finally, cells were stained with phalloidin-Alexa488 (Thermo Fisher Scientific) and/or
LipidTOX Green (Thermo Fisher Scientific) for 30 min according to the manufacturers’
instructions, and/or 50 μg/ml Filipin complex from Streptomyces filipinensis (Sigma-
Aldrich) for 2 h at room temperature in the dark. Lysotracker and filipin pictures were
taken using a SP8WLL confocal microscope (Leica, Amsterdam, The Netherlands). Galec-
tin-3 and NDP52 colocalization was visualized using a Dragonfly spinning-disk confocal
microscope (Andor Technologies, Belfast, UK) equipped with 405, 488, 561 and 640nm
lasers and a Zyla 4.2 sCMOS camera.
Colocalization analysis
Macrophages were infected for 4 h with a DsRed-expressing Mtb H37Rv strain at a MOI of
10:1 and stained with Lysotracker Deep Red or primary antibodies for galectin 3 and
NDP52 as described above. Lysotracker channel background was subtracted by rolling ball
algorithm (20 pixel radius). All images were analyzed using CellProlifer 3.0.0 [106]. First,
pictures were corrected for non-homogenous illumination if necessary. DsRed-Mtb were
segmented by manual global thresholding with intensity-based declumping, and stained
objects were segmented by adaptive two-class Otsu thresholding with upper and lower
bounds to correct for individual cell-specific differences in background signal with inten-
sity-based declumping. Then, the percentage of staining object overlap with individual
DsRed-Mtb was calculated for each image and the average colocalization was calculated for
each treatment condition.
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Macrophage viability assay
To assess cell viability after treatment and infection with H37Rv Mtb, macrophages were
stained with 2 μg/ml propidium iodide (PI) (Sigma-Aldrich) and 2 μg/ml Hoechst 33342
(Sigma-Aldrich) in RPMI without phenol red and FCS for 5 min in the dark. Cells were subse-
quently imaged on a AF6000 fluorescence microscope (Leica) and pictures were taken at a 20x
magnification. Pictures were processed and analyzed in Image J. First, the background was
subtracted by rolling ball algorithm (20 pixel radius). Then, Hoechst- or PI-positive nuclei
were segmented by Otsu thresholding and counted, from which the percentages of viable mac-
rophages were calculated. Staurosporin (5 μM) (Sigma-Aldrich) was used as a positive control
for cell death.
Statistical analysis
Statistical significance was assessed by Kruskal-Wallis test with post-hoc Dunn’s test, or Wil-
coxon signed rank test using GraphPad software (version 7.02, Prism, La Jolla, CA, USA) with
post-hoc false discovery rate (FDR) correction for multiple comparisons when necessary. Sta-
tistical analysis of patients characteristics was performed in SPSS 23 (IBM, Armonk, NY, USA)
by one-way ANOVA (reported p-values are the outcome of the F-test), independent samples t-
test or chi-squared test.
Supporting information
S1 Fig. Macrophage phenotype and Oil Red O staining. Monocyte-derived macrophages
were differentiated using M-CSF (50 ng/ml) for 6 days. (A) Histograms of the cell surface
expression of CD14 and CD163 as determined by flow cytometry. Stained (blue) and
unstained (blue) samples are displayed. Data shown are from one representative donor. (B)
Macrophages were treated overnight with PBS control, LDL, acLDL or oxLDL at 25 μg/ml and
stained for neutral lipids with Oil Red O. Staining was dissolved and quantified by measuring
OD at 520 nm. Data are displayed as ΔOD520 versus PBS control. Individual donors are
depicted as dots with group medians. Statistical significance was determined by Kruskal-Wallis
test with post-hoc Dunn’s test. �� = p< 0.01. (C) Macrophages were treated with 25 μg/ml
oxLDL or PBS control overnight and infected with Mtb H37Rv for 24 h. OxLDL-induced
increased Mtb loads were normalized to PBS control and plotted versus the infectious load
(MOI) as determined by CFU assay (n = 34; each dot represents one individual donor). Ken-
dall tau correlation and associated two-sided p-value are displayed.
(TIF)
S2 Fig. oxLDL treatment diminished macrophage antigen presentation to a second CD4
+ T cell clone and this was independent of cell surface expression of CD86, CD80 and
HLA-DR. Primary human macrophages were treated with PBS control, native LDL or oxLDL
(1, 10 or 25 μg/ml) overnight. (A) Macrophages were co-cultured for four days with the
HLA-DR3-restricted CD4+ T cell Rp15 1–1 at a ratio of 1:4 and 0.1, 1 or 10 μg/ml of its cog-
nate peptide or 1.25 μg/ml PPD. T cell proliferation was measured by tritium-thymidine incor-
poration during the last 24 h (n = 3). Data is represented as means with standard deviations.
(B) Cell surface expression of CD86, CD80 and HLA-DR as determined by flow cytometry of
macrophages treated overnight with PBS, native LDL or oxLDL (25 μg/ml). Stained (blue) and
unstained (blue) samples are displayed. Data shown are from one representative donor (n = 3).
(C) Primary human macrophages were treated overnight with PBS control (n = 15), acLDL
(n = 9), oxLDL (n = 15) or native LDL (n = 6) (25 μg/ml) and subsequently infected with Mtb
H37Rv at a MOI of 10:1. Cells were lysed directly after 1 h of infection and bacterial load was
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determined by CFU assay to determine Mtb uptake. Results were normalized versus PBS con-
trol and depicted as group medians with 95% confidence intervals.
(TIF)
S3 Fig. U18666A and oxLDL increased protein markers of lysosomes and autophagy in
Mtb-infected macrophages without affecting cell viability. Primary human macrophages
were treated with PBS control, acLDL or oxLDL (25 μg/ml) for 24 h prior to infection with
Mtb H37Rv at a MOI of 10:1. (A) Representative Western Blot result of Cathepsin D protein
levels from macrophages treated with bafilomycin A1 (10 nM) or DMSO, showing protein
bands of both the mature heavy chain (34 kDa) and the processing intermediate pro-cathepsin
D (48 kDa) after 30 and 900 seconds of exposure time. Pro-cathepsin D levels were first nor-
malized to actin and subsequently versus PBS control (n = 4). (B) Western blot analysis of lyso-
somal and autophagy markers in macrophages co-treated with PBS, oxLDL or acLDL (25 μg/
ml) and U18666A (3 μg/ml), bafilomycin A1 (10 nM) or DMSO control during 24 h of H37Rv
Mtb infection. Data shown is from one representative donor (n = 2). (C) Mtb-infected macro-
phages were stained with Hoechst and PI to determine cell viability. Staurosporin (5 μM) and
PBS were used as positive and negative control for cell death. (D) Percentages of viable cells
(Hoechts+/PI-). Data are displayed as means with standard deviations (n = 4).
(TIF)
S4 Fig. Kinetic analysis of intracellular Mtb survival and associated cytokine responses in
human macrophages. Primary human macrophages were treated with PBS control, acLDL or
oxLDL (25 μg/ml) overnight and subsequently infected with Mtb H37Rv at a MOI of 10:1.
Cells were lysed at 0 (uptake), 4, 24, 48, 72 and 144 h post-infection for CFU analysis (n = 7).
(A) Intracellular Mtb loads are depicted as fraction of uptake in Tukey’s boxplots for each time
point and condition: PBS (white), acLDL (grey) and oxLDL (red). (B) Supernatants were har-
vested at each time point post-infection and cytokine concentrations were determined by mul-
tiplex assay. Levels of IL-10, IL-6, TNF-α, IL-8, IL-1RA, CXCL10, IFNα2, CCL2, CCL3, CCL4,
G-CSF, VEGF and GM-CSF (pg/ml) are depicted in Tukey’s boxplots for each time point and
condition: PBS (green), acLDL (purple) and oxLDL (red). Group medians are shown as dashed
lines. Statistical significance was determined by Wilcoxon signed rank test with post-hoc FDR
correction. p< 0.05 for � = PBS vs oxLDL, # = oxLDL vs acLDL, ‡ = PBS vs acLDL.
(TIF)
S1 Table. Patient clinical characteristics according to disease group (n = 79). Data is pre-
sented as percentage of total (%) or mean ± SD, �Point-of-care measurements, †lab measure-
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